Skip Navigation

Link to  the National Institutes of Health NIDA NEWS NIDA News RSS Feed
The Science of Drug Abuse and Addiction from the National Institute on Drug Abuse Keep Your Body Healthy
Go to the Home pageGo to the About Nida pageGo to the News pageGo to the Meetings & Events pageGo to the Funding pageGo to the Publications page
PhysiciansResearchersParents/TeachersStudents/Young AdultsEn Español Drugs of Abuse & Related Topics

NIDA Home > Publications > Research Reports    

Research Report Series - Heroin Abuse and Addiction




Heroin abuse during pregnancy and its many associated environmental factors (e.g., lack of prenatal care) have been associated with adverse consequences including low birth weight, an important risk factor for later developmental delay. Methadone maintenance combined with prenatal care and a comprehensive drug treatment program can improve many of the detrimental maternal and neonatal outcomes associated with untreated heroin abuse, although infants exposed to methadone during pregnancy typically require treatment for withdrawal symptoms. In the United States, several studies have found buprenorphine to be equally effective and as safe as methadone in the adult outpatient treatment of opioid dependence. Given this efficacy among adults, current studies are attempting to establish the safety and effectiveness of buprenorphine in opioid-dependent pregnant women. For women who do not want or are not able to receive pharmacotherapy for their heroin addiction, detoxification from opiates during pregnancy can be accomplished with relative safety, although the likelihood of relapse to heroin use should be considered.


Why are heroin users at special
risk for contracting HIV/AIDS
and hepatitis B and C?


Heroin users are at risk for contracting HIV, hepatitis C (HCV), and other infectious diseases, through sharing and reuse of syringes and injection paraphernalia that have been used by infected individuals, or through unprotected sexual contact with an infected person. Injection drug users (IDUs) represent the highest risk group for acquiring HCV infection; an estimated 70 to 80 percent of the 35,000 new HCV infections occurring in the United States each year are among IDUs.

NIDA-funded research has found that drug abusers can change the behaviors that put them at risk for contracting HIV through drug abuse treatment, prevention, and community-based outreach programs. They can eliminate drug use, drug-related risk behaviors such as needle sharing, unsafe sexual practices, and, in turn, the risk of exposure to HIV/AIDS and other infectious diseases. Drug abuse prevention and treatment are highly effective in preventing the spread of HIV.


Index

Letter from the Director

What is heroin?

What is the scope of heroin use in the United States?

How is heroin used?

What are the immediate (short-term) effects of heroin use?

What are the long-term effects of heroin use?

What are the medical complications of chronic heroin use?

How does heroin abuse affect pregnant women?

Why are heroin users at special risk for contracting HIV/AIDS and hepatitis B and C?

What are the treatments for heroin addiction?

What are the opioid analogs and their dangers?

Where can I get further scientific information about heroin abuse and addiction?

Glossary and References

 

Heroin Abuse and Addiction Research Report Cover



NIDA Home | Site Map | Search | FAQs | Accessibility | Privacy | FOIA (NIH) | Employment | Print Version


National Institutes of Health logo_Department of Health and Human Services Logo The National Institute on Drug Abuse (NIDA) is part of the National Institutes of Health (NIH) , a component of the U.S. Department of Health and Human Services. Questions? See our Contact Information. Last updated on Tuesday, July 22, 2008. The U.S. government's official web portal